Literature DB >> 11311133

Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors.

G Boileau1, H S Tenenhouse, L Desgroseillers, P Crine.   

Abstract

Mutations in the PHEX gene (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) are responsible for X-linked hypophosphataemia, and studies in the Hyp mouse model of the human disease implicate the gene product in the regulation of renal phosphate (P(i)) reabsorption and bone mineralization. Although the mechanism for PHEX action is unknown, structural homologies with members of the M13 family of endopeptidases suggest a function for PHEX protein in the activation or degradation of peptide factors involved in the control of renal P(i) transport and matrix mineralization. To determine whether PHEX has endopeptidase activity, we generated a recombinant soluble, secreted form of human PHEX (secPHEX) and tested the activity of the purified protein with several peptide substrates, including a variety of bone-related peptides. We found that parathyroid-hormone-related peptide(107-139) is a substrate for secPHEX and that the enzyme cleaves at three positions within the peptide, all located at the N-terminus of aspartate residues. Furthermore, we show that osteocalcin, PP(i) and P(i), all of which are abundant in bone, are inhibitors of secPHEX activity. Inhibition of secPHEX activity by osteocalcin was abolished in the presence of Ca(2+). We suggest that PHEX activity and mineralization may be controlled in vivo by PP(i)/P(i) and Ca(2+) and, in the latter case, the regulation requires the participation of osteocalcin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311133      PMCID: PMC1221786          DOI: 10.1042/bj3550707

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Increased bone formation in osteocalcin-deficient mice.

Authors:  P Ducy; C Desbois; B Boyce; G Pinero; B Story; C Dunstan; E Smith; J Bonadio; S Goldstein; C Gundberg; A Bradley; G Karsenty
Journal:  Nature       Date:  1996-08-01       Impact factor: 49.962

Review 2.  Phosphatonin--a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia)

Authors:  R Kumar
Journal:  Nephrol Dial Transplant       Date:  1997-01       Impact factor: 5.992

3.  C-terminal parathyroid hormone-related protein inhibits proliferation and differentiation of human osteoblast-like cells.

Authors:  M E Martínez; A García-Ocaña; M Sánchez; S Medina; T del Campo; A Valin; M J Sanchez-Cabezudo; P Esbrit
Journal:  J Bone Miner Res       Date:  1997-05       Impact factor: 6.741

4.  Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse.

Authors:  D Lajeunesse; R A Meyer; L Hamel
Journal:  Kidney Int       Date:  1996-11       Impact factor: 10.612

5.  Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice.

Authors:  L Beck; Y Soumounou; J Martel; G Krishnamurthy; C Gauthier; C G Goodyer; H S Tenenhouse
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Secretion of a type II integral membrane protein induced by mutation of the transmembrane segment.

Authors:  I Lemire; C Lazure; P Crine; G Boileau
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

7.  cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.

Authors:  L Du; M Desbarats; J Viel; F H Glorieux; C Cawthorn; B Ecarot
Journal:  Genomics       Date:  1996-08-15       Impact factor: 5.736

8.  Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11.

Authors:  K Shimada; M Takahashi; A J Turner; K Tanzawa
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

9.  Expression of parathyroid hormone-related protein in cells of osteoblast lineage.

Authors:  N Suda; M T Gillespie; K Traianedes; H Zhou; P W Ho; D K Hards; E H Allan; T J Martin; J M Moseley
Journal:  J Cell Physiol       Date:  1996-01       Impact factor: 6.384

Review 10.  Defining the roles of parathyroid hormone-related protein in normal physiology.

Authors:  W M Philbrick; J J Wysolmerski; S Galbraith; E Holt; J J Orloff; K H Yang; R C Vasavada; E C Weir; A E Broadus; A F Stewart
Journal:  Physiol Rev       Date:  1996-01       Impact factor: 37.312

View more
  15 in total

1.  Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein.

Authors:  Marcelo Campos; Constance Couture; Izaura Y Hirata; Maria A Juliano; Thomas P Loisel; Philippe Crine; Luiz Juliano; Guy Boileau; Adriana K Carmona
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Amelotin is expressed in retinal pigment epithelium and localizes to hydroxyapatite deposits in dry age-related macular degeneration.

Authors:  Dinusha Rajapakse; Katherine Peterson; Sanghamitra Mishra; Jianguo Fan; Joshua Lerner; Maria Campos; Graeme Wistow
Journal:  Transl Res       Date:  2020-02-27       Impact factor: 7.012

3.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

Review 4.  Tooth dentin defects reflect genetic disorders affecting bone mineralization.

Authors:  S Opsahl Vital; C Gaucher; C Bardet; P S Rowe; A George; A Linglart; C Chaussain
Journal:  Bone       Date:  2012-01-26       Impact factor: 4.398

5.  Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice.

Authors:  B Zhang; Y Sun; L Chen; C Guan; L Guo; C Qin
Journal:  Oral Dis       Date:  2010-03-09       Impact factor: 3.511

6.  DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.

Authors:  Bettina Lorenz-Depiereux; Murat Bastepe; Anna Benet-Pagès; Mustapha Amyere; Janine Wagenstaller; Ursula Müller-Barth; Klaus Badenhoop; Stephanie M Kaiser; Roger S Rittmaster; Alan H Shlossberg; José L Olivares; César Loris; Feliciano J Ramos; Francis Glorieux; Miikka Vikkula; Harald Jüppner; Tim M Strom
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

7.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

8.  Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets.

Authors:  Céline Gaucher; Tchilalo Boukpessi; Dominique Septier; Frédéric Jehan; Peter S Rowe; Michèle Garabédian; Michel Goldberg; Catherine Chaussain-Miller
Journal:  Cells Tissues Organs       Date:  2008-08-14       Impact factor: 2.481

Review 9.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

10.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.